179554-33-7

Basic information

• Product Name: 2,6-dimethyl-3-(chloromethyl)benzoic acid
• Synonyms: 2,6-dimethyl-3-(chloromethyl)benzoic acid
• CAS NO: 179554-33-7
• Molecular Weight: 198.649
• Mol File: 179554-33-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2,6-dimethyl-3-(chloromethyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dimethyl-3-(chloromethyl)benzoic acid(179554-33-7)
• EPA Substance Registry System: 2,6-dimethyl-3-(chloromethyl)benzoic acid(179554-33-7)

Safety Data

• Hazardous Substances Data: 179554-33-7(Hazardous Substances Data)

Usage

Derivative of benzoic acid

It is a modified form of benzoic acid a simple aromatic carboxylic acid.

Methyl and chloromethyl groups

Contains two methyl groups (CH3) and one chloromethyl group (CH2Cl) attached to the benzene ring, which influence its chemical reactivity and properties.

Use as an intermediate

It is often used as an intermediate in the synthesis of pharmaceuticals and other organic compounds, making it a versatile building block in organic chemistry.

Potential biological activity

2,6-dimethyl-3-(chloromethyl)benzoic acid is known for its potential biological activity, including anti-inflammatory and antimicrobial properties, which may contribute to its use in medicine.

Building block for functionalized benzene derivatives

The presence of the chloromethyl group makes it a valuable building block for the synthesis of various functionalized benzene derivatives, further expanding its applications in organic chemistry and related fields.

Upstream product

• 50-00-0 formaldehyd 
• 632-46-2 2,6-dimethylbenzoic acid 

Relevant articles and documents

New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: Design, synthesis, and biopharmacological properties

In a preliminary work, we reported two NO-sartans, possessing the characteristics of an AT1 antagonist and a "slow NO donor", obtained by adding NO-donor side chains to losartan 1. The NO release from an NO-sartan should be modulated in order to strengthen the antihypertensive activity of the native drug and to ensure additional effects, such as the antiplatelet and anti-ischemic ones. To obtain a collection of proto-typical NO-sartans, showing different rates of NO release, new NO-donor moieties have been linked to 1 or its active metabolite 2 (EXP 3174). Almost all the synthesized compounds exhibited both AT1-antagonist and NO-mediated vasorelaxing properties, with a wide range of NO-releasing rates. Further pharmacological investigation on compound 4a showed that it possessed antihypertensive and cardiac antihypertrophic effects similar to those of the reference AT1-blocking or ACE-inhibiting drugs. Furthermore, the additional anti-ischemic cardio-protective properties and antiplatelet effects of 4a have been preliminarily investigated.